نتایج جستجو برای: dasatinib

تعداد نتایج: 1954  

Journal: :Cancer research 2005
Sangkil Nam Donghwa Kim Jin Q Cheng Shumin Zhang Ji-Hyun Lee Ralf Buettner Janni Mirosevich Francis Y Lee Richard Jove

Src family kinases (SFK) are currently being investigated as targets for treatment strategies in various cancers. The novel SFK/Abl inhibitor, dasatinib (BMS-354825), is a promising therapeutic agent with oral bioavailability. Dasatinib has been shown to inhibit growth of Bcr-Abl-dependent chronic myeloid leukemia xenografts in nude mice. Dasatinib also has been shown to have activity against c...

2016
Fidencio Davalos Benjamin Chaucer Wahib Zafar Shamim Salman Jay Nfonoyim

Dasatinib is a common anticancer drug used in the treatment of leukemia. Several side effects have been reported, the most common being myelosuppression, diarrhea, edema, and nausea. Three papers have been published reporting hepatic side effects of dasatinib treatment. A rare side effect of dasatinib treatment is reactivation of latent cytomegalovirus (CMV) infection. Never before has dasatini...

2017
Aya Nakaya Yoshiko Azuma Shinya Fujita Atsushi Satake Takahisa Nakanishi Yukie Tsubokura Akiko Konishi Masaaki Hotta Hideaki Yoshimura Kazuyoshi Ishii Tomoki Ito Shosaku Nomura

A 69-year-old man with chronic-phase chronic myeloid leukemia was initially treated with 100 mg dasatinib once a day. Despite a major molecular response within 9 months, he developed hemorrhagic colitis 32 months after starting dasatinib. Colonoscopy identified multiple hemorrhagic ulcers in the transverse colon. The pathological findings indicated cytomegalovirus infection. Dasatinib was stopp...

Journal: :Circulation 2012
David Montani Emmanuel Bergot Sven Günther Laurent Savale Anne Bergeron Arnaud Bourdin Helene Bouvaist Matthieu Canuet Christophe Pison Margareth Macro Patrice Poubeau Barbara Girerd Delphine Natali Christophe Guignabert Frédéric Perros Dermot S O'Callaghan Xavier Jaïs Pascale Tubert-Bitter Gérard Zalcman Olivier Sitbon Gérald Simonneau Marc Humbert

BACKGROUND The French pulmonary hypertension (PH) registry allows the survey of epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have chronic myelogenous leukemia treated with the tyrosine kinase inhibitor dasatinib. METHODS AND RESULTS This study was designed to describe incident cases of dasatinib-associated PH reported in the French PH registry. ...

2016
Amol Shindikar Gandhali Deshpande Umesh Chaudhari Dimple Bhatia Kalpana Joshi

Purpose: This study compared the in vitro activity of small molecule tyrosine kinase inhibitors (TKI’s) erlotinib, dasatinib and sorafenib in human cancer cell lines of different tumor origins HCT 116 (colon carcinoma), MCF7 (breast carcinoma) and H460 (non-small cell lung carcinoma). Methods: Cytotoxicity assay was performed to determine the IC50 concentrations of TKI’s-erlotinib, dasatinib, s...

Journal: :Gynecologic oncology research and practice 2014
Micael Lopez-Acevedo Lisa Grace Deanna Teoh Regina Whitaker David J Adams Jingquan Jia Andrew B Nixon Angeles Alvarez Secord

BACKGROUND To explore the activity of dasatinib alone and in combination with gemcitabine and docetaxel in uterine leiomyosarcoma (uLMS) cell lines, and determine if dasatinib inhibits the SRC pathway. METHODS SK-UT-1 and SK-UT-1B uLMS cells were treated with gemcitabine, docetaxel and dasatinib individually and in combination. SRC and paxcillin protein expression were determined pre- and pos...

2017
Aaron J Scott Eun-Kee Song Stacey Bagby Alicia Purkey Martin McCarter Csaba Gajdos Kevin S Quackenbush Benjamin Cross Todd M Pitts Aik Choon Tan S Gail Eckhardt Hubert Fenton John Arcaroli Wells A Messersmith

BACKGROUND Dysregulation of the Src pathway has been shown to be important at various stages of cancer. Dasatinib is a potent Src/Abl inhibitor and has demonstrated to have anti-proliferative and anti-invasive activity in many preclinical models. The objective of this study was to determine the anti-tumor activity of dasatinib using in vitro and in vivo preclinical colorectal (CRC) models. ME...

Journal: :Haematologica 2011
Ahmet Emre Eskazan Teoman Soysal Seniz Ongoren Emine Gulturk Burhan Ferhanoglu Yildiz Aydin

We read with interest the paper about pleural and pericardial effusion in chronic myeloid leukemia during lowdose dasatinib treatment by Krauth et al. They reported 4 patients who developed effusions with 50 or 100 mg daily dasatinib out of a total number of 13 patients. Pleural and pericardial effusions were grade III/IV in 2 of the patients. There were no reports of pre-existing cardiac or pu...

Journal: :Cancer discovery 2011
Peter S Hammerman Martin L Sos Alex H Ramos Chunxiao Xu Amit Dutt Wenjun Zhou Lear E Brace Brittany A Woods Wenchu Lin Jianming Zhang Xianming Deng Sang Min Lim Stefanie Heynck Martin Peifer Jeffrey R Simard Michael S Lawrence Robert C Onofrio Helga B Salvesen Danila Seidel Thomas Zander Johannes M Heuckmann Alex Soltermann Holger Moch Mirjam Koker Frauke Leenders Franziska Gabler Silvia Querings Sascha Ansén Elisabeth Brambilla Christian Brambilla Philippe Lorimier Odd Terje Brustugun Aslaug Helland Iver Petersen Joachim H Clement Harry Groen Wim Timens Hannie Sietsma Erich Stoelben Jürgen Wolf David G Beer Ming Sound Tsao Megan Hanna Charles Hatton Michael J Eck Pasi A Janne Bruce E Johnson Wendy Winckler Heidi Greulich Adam J Bass Jeonghee Cho Daniel Rauh Nathanael S Gray Kwok-Kin Wong Eric B Haura Roman K Thomas Matthew Meyerson

UNLABELLED While genomically targeted therapies have improved outcomes for patients with lung adenocarcinoma, little is known about the genomic alterations which drive squamous cell lung cancer. Sanger sequencing of the tyrosine kinome identified mutations in the DDR2 kinase gene in 3.8% of squamous cell lung cancers and cell lines. Squamous lung cancer cell lines harboring DDR2 mutations were ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Lajos Pusztai Stacy Moulder Mehmet Altan Danielle Kwiatkowski Vicente Valero Naoto T Ueno Francisco J Esteva Rony Avritscher Yuan Qi Lewis Strauss Gabriel N Hortobagyi Christos Hatzis W Fraser Symmans

PURPOSE Dasatinib has limited single-agent activity in unselected patients with metastatic breast cancer. Several gene signatures predictive of dasatinib response in vitro have been reported. The purpose of this three-arm, phase II study was to prospectively assess the utility of three previously published gene signatures to select patients with clinical benefit from dasatinib. EXPERIMENTAL D...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید